TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema

Completed · Phase 4

Conditions studied: Macular Edema, Uveitis

In brief

The purpose of this study is to determine whether an intravitreal dexamethasone implant (Ozurdex, Allergan) is effective to manage macular edema secondary to non-infectious uveitis.

Key facts

Study ID

NCT01870440

Run by

Northern California Retina Vitreous Associates

People needed

10

Starts

2013-05-01

Expected to finish

2015-02-01

Last updated by the study team

2015-03-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Uveitis CME with central subfoveal thickness > 350 microns
• non-infectious uveitis
• Visual Acuity > 20/32

You may not qualify if…

• Visual Acuity worse than 20/200
• Moderate or severe glaucoma (as defined as >2 topical ocular medications)
• Infectious uveitis
• Patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis, vaccinia, varicella, mycobacterial infections, and fungal diseases.
• Aphakic eyes with rupture of the posterior lens capsule
• Anterior Chamber intraocular Lens and rupture of the posterior lens capsule
• Hypersensitivity to any components of the Ozurdex

Where it is running

• Northern California Retina Vitreous Associates — Mountain View, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.